-
Ariad Pharmaceutical, et al v. Eli Lilly & CO. NPE DC
- 1:02-cv-11280
- D. Mass.
- Judge: Rya W. Zobel
- Filed: 06/25/2002
- Closed: 09/10/2007
- Latest Docket Entry: 06/04/2010
- PACER
4
Plaintiffs
1
Defendant
2
Accused
Products
1
Patent-in-Suit
1,904
Days in
Litigation
-
Ariad Pharmaceutical, et al v. Eli Lilly & CO. NPE DC
- 1:02-cv-11280
- D. Mass.
- Judge: Rya W. Zobel
- Filed: 06/25/2002
- Closed: 09/10/2007
- Latest Docket Entry: 06/04/2010
- PACER
Cause of Action
Infringement
Market Sector
Biotech and Pharma
Assigned Judge
Outcome Summary
Patent Information
-
Validity & Enforceability
| Claim # | Claim Text | Outcome |
|---|---|---|
| 80 |
The method of claim 8 wherein reducing NF-κB activity comprises reducing binding of NF-κB to NF-κB recognition sites on genes which are transcriptionally regulated by NF-κB.
|
Valid (102 and 112)
Entry 346 |
| 95 |
The method of claim 9, carried out on human cells.
|
Valid (102 and 112)
Entry 346 |
| 144 |
The method of claim 14 wherein reducing NF-κB activity comprises reducing binding of NF-κB to NF-κB recognition sites on genes which are transcriptionally regulated by NF-κB.
|
Valid (102 and 112)
Entry 346 |
| 145 |
The method of claim 14, carried out on human cells.
|
Valid (102 and 112)
Entry 346 |
-
Infringement
Eli Lilly and Company
- 1 Detail
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| EvistaXigris | US 6,410,516 B1 |
80, 95, 144, 145
|
Infringement
Entry 417Entry 346 |
-
Damages